MYRIAD GENETICS, INC. Selling and Marketing Expense
MYRIAD GENETICS, INC. (MYGN) reported Selling and Marketing Expense of $83.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-07-31
- MYRIAD GENETICS, INC. selling and marketing expense for the quarter ending 2026-06-30 was $83.10M, a 15.58% increase year-over-year.
- MYRIAD GENETICS, INC. selling and marketing expense for the quarter ending 2026-03-31 was $73.60M, a 6.36% increase year-over-year.
- MYRIAD GENETICS, INC. selling and marketing expense for the quarter ending 2025-12-31 was $68.70M, a 4.58% decline year-over-year.
- MYRIAD GENETICS, INC. selling and marketing expense for the quarter ending 2025-09-30 was $71.00M, a 1.57% increase year-over-year.
- MYRIAD GENETICS, INC. selling and marketing expense for fiscal 2025 was $280.80M, a 1.16% decline from fiscal 2024.
- MYRIAD GENETICS, INC. selling and marketing expense for fiscal 2024 was $284.10M, a 1.76% decline from fiscal 2023.
- MYRIAD GENETICS, INC. selling and marketing expense for fiscal 2023 was $289.20M, a 8.40% increase from fiscal 2022.
- MYRIAD GENETICS, INC. selling and marketing expense for fiscal 2022 was $266.80M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $83.10M 10-Q · filed 2026-07-31 | $156.70M 10-Q · filed 2026-07-31 | $225.40M derived: sum of 3 quarters · filed 2026-07-31 | $296.40M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $73.60M 10-Q · filed 2026-05-06 | $142.30M derived: sum of 2 quarters · filed 2026-05-06 | $213.30M derived: sum of 3 quarters · filed 2026-05-06 | $285.20M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $68.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $139.70M derived: sum of 2 quarters · filed 2026-02-24 | $211.60M derived: sum of 3 quarters · filed 2026-07-31 | $280.80M 10-K · filed 2026-02-24 |
| 2025-09-30 | $71.00M 10-Q · filed 2025-11-04 | $142.90M derived: sum of 2 quarters · filed 2026-07-31 | $212.10M 10-Q · filed 2025-11-04 | $284.10M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $71.90M 10-Q · filed 2026-07-31 | $141.10M 10-Q · filed 2026-07-31 | $213.10M derived: sum of 3 quarters · filed 2026-07-31 | $283.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $69.20M 10-Q · filed 2026-05-06 | $141.20M derived: sum of 2 quarters · filed 2026-05-06 | $211.10M derived: sum of 3 quarters · filed 2026-05-06 | $283.90M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $72.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $141.90M derived: sum of 2 quarters · filed 2026-02-24 | $214.70M derived: sum of 3 quarters · filed 2026-02-24 | $284.10M 10-K · filed 2026-02-24 |
| 2024-09-30 | $69.90M 10-Q · filed 2025-11-04 | $142.70M derived: sum of 2 quarters · filed 2025-11-04 | $212.10M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $72.80M 10-Q · filed 2025-08-06 | $142.20M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $69.40M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $289.20M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $266.80M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |